Celltrion's 'Remsima' achieves No. 1 market share in Japan's autoimmune disease treatment market
Remsima, an autoimmune disease treatment developed by Celltrion, a leading South Korean bio company, has achieved significant success in the Japanese market. Eleven years after its entry into Japan, Remsima has recorded the number one market share, proving the excellence of South Korean pharmaceuticals.
Remsima is a biosimilar product containing infliximab and is used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease. While the Japanese market has been known for its extremely stringent quality standards, Celltrion has steadily increased its market share based on consistent quality control and trust.
This achievement of reaching the top spot is significant in that it demonstrates the competitiveness of South Korean pharmaceutical companies in the global market. In particular, the success in the Japanese market is expected to serve as an opportunity to raise awareness of Celltrion's products across the entire Asian market.
A Celltrion official stated that the company will continue to strive to provide better treatment options for medical staff and patients in Japan. With this achievement as a stepping stone, the industry's attention is focused on what steps Celltrion will take next in the global market.